Importantly, treatment with fruquintinib remodeled the tumor immune microenvironment of MC38 tumors by increasing the percentages of CD4+ and CD8+ T cells and selectively reducing myeloid cells, particularly CD11b+ populations of tumor-associated macrophages (TAMs) and type 2 dendritic cells. This evidence concerns the gene CD4 and neoplasm.